HomeMy WebLinkAboutFully executed contract. Docusign Envelope lD: 700826AD-3CE3-815C-8194-01 3EF364M04
WHEREAS, HCA and Contractor entered into Contract K5885 for the development and implementation of the
Medication for Opioid Use Disorder (MOUD) and Medications for Alcohol Use Disorder (MAUD) in Jails
programs, and;
WHEREAS, HCA and Contractor wish to amend the Contract pursuant to Section 4.3, Amendmenfs, to extend
the Contract term, increase funding, and incorporate a revised and restated Statement of Work;
THEREFORE, the parties agree the Contract is amended as follows:
1. Contract Section 2, Definitions, two (2) new defined terms are incorporated in alphabetical order. The
new defined terms are as follows:
"lnformed Refusal" is when an individual refuses treatment after an explanation of the treatment is
provided including, its benefits and risks, alternatives, addressing the individual's concerns and
exploration of any reasonable way of addressing the concerns to avoid refusal, and explanation of the
risks of refusal, all this provided in a manner that is comprehensible by the individual.
"Appears Unwell" means to demonstrate signs, symptoms, or indications observable by a layperson
that (1) indicate an individual may be sick (physically or psychologically); or (2) in the case of a patient
who has already been assessed by a qualified health care professional, indicate the individual's condition
is worsening, becoming unstable, or becoming a danger to themselves or others
2. Contract Section 3.2, Term, subsection 3.2.1, is amended to extend the Contract term as follows:
3.2.1 The initial term of the Contract will commence on March 1 , 2022, and continue through June 30,
2027, unless terminated sooner as provided herein.
3. Contract Section 3.3, Compensation, subsection 3.3.1 is amended to reflect the $209,000 increase in
funding, subsection 3.3.1 now reads as follows:
3.3.1 The parties have determined the cost of accomplishing the work herein will not exceed
$1,435,775, inclusive of all fees, taxes, and expenses. Compensation for satisfactory performance
of the work will not exceed this amount unless the parties agree to a higher amount through an
amendment.
Washington State
Health Care thority
CONTRACT
AMENDMENT
HCA Contract No.: K5885
Amendment No.: 05
THIS AMENDMENT TO THE CONTRACT is between the Washington State Health Care Authority and the party
whose name appears below, and is effective as of the date set forth below
CONTRACTOR NAME
Kittitas County
CONTRACTOR doing business as (DBA)
Kittitas Cou nty Sheriff-Jail
CONTRACTOR ADDRESS
205 W 5th Avenue, Suite 1
Ellensburg, WA 98926
CONTRACTOR MANAGER
Name: Edward Buntin
Email: edward. buntin@co. kittitas.wa. us
AMENDMENT START DATE
July 1 ,2026
CONTRACT END DATE
June 30,2027
PRIOR MAXIMUM CONTRACT AMOUNT
$1,226,775
AMOUNT OF INCREASE
$209,000
TOTAL MAXIMUM COMPENSATION
$1,435,775
HCA Contract No. K5885-05 Page 1 of 13
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04
4. A new Schedule A-5, Sfafem ent of Work, is added to prevent redundancy between the previous
Schedule A(s), Sfafem ent(s) of Work, while also incorporating updates. ln the event of an inconsistency
the revised and restated Schedule A-5, Sfafement of Work, shall supersede all previous Schedule A(s),
Statement(s) of Work.
The revised and restated Schedule A-5, Sfafement of Work, is attached hereto and by this reference is
incorporated into the Contract.
5. A new Attachment 1-A, EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report, is added
to provide Contractor with the new reporting template to be required beginning July 1,2026. The updated
Attachment 1-A, EXAMPLE - MOIJD & MAUD in Jails Program Monthly Progress Report, is attached
hereto and by this reference is incorporated into the Contract'
6. This Amendment is effective July '1, 2026, ("Efiective Date").
7. All capitalized terms not otherwise defined herein have the meaning ascribed to them in the Contract.
8. All other terms and conditions of the Contract remain unchanged and in full force and effect.
The parties signing below warrant that they have read and understand this Amendment and have authority to
execute the Amendment. This Amendment will be binding on HCA only upon signature by both parties.
DATE SIGNED
5t26t2026
PRINTED NAME AND TITLE
Clay Myers
Sheriff
CONTRACTOR SIGNATURE
-Signed
by:
(J-at, lutury
DATE SIGNED
5t26t2026
PRINTED NAME AND TITLE
\ndria Howerton
HCA Deputy Contracts Administrator
by:
JaS*^z
HCA Contract No. K5885-05 Page 2 of 13
Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364M04
SCHEDULE A-5
Statement of Work
1. PURPOSE
To support a comprehensive treatment program for incarcerated individuals with Opioid Use Disorder (OUD)
and Alcohol Use Disorder (AUD), beginning with screening upon entry and ending with seamless transition to
care in the community, with use of Medications for Opioid Use Disorder (MOUD) and Medications for Alcohol
Use Disorder (MAUD) at its core.
This Contract supports RCW 71.24.599: Opioid use disorder-Citv and countv iails-Fundinq. (wa.qov).
Health Equity - This program also intends to address inequities in treatment and recovery services by
providing medically necessary treatment to incarcerated individuals. Programs should understand cultural
barriers and provide culturally appropriate services. Additionally, this program intends to identify stigma and
educate to ensure ongoing collaboration and openness to change.
2. PERFORMANCE EXPECTATIONS
ln addition to the performance expectations outlined in Contract Section 3.1, Performance Expecfafions, the
following expectations are also required, as applicable:
2.1. Treatment Requirements for American Indian/Alaska Native (A!/AN) lndividuals
For American lndian/Alaska Native (AliAN) individuals receiving Medications for Opioid Use Disorder
(MOUD) and/or Medications for Alcohol Use Disorder (MAUD) services, Contractor, shall coordinate
with the individual's lndian Health Care Provider (IHCP) to ensure the IHCP can participate in treatment
and discharge planning, including continuity of care in the nearest IHCP clinically appropriate setting.
3. WORK EXPECTATIONS
Contractor shall ensure funds are responsibly used towards the Opioid Use Disorder (OUD) and Alcohol Use
Disorder (AUD) treatment programs in the jail and provide the community standard of care, including, at a
minimum, the following core components:
3.1. General Requirements
3.1.1. Unless otherwise stated in this Statement of Work, Section 3, Work Expectations, Contractor
shallfollow Guidelines for Manaqinq Substance Withdrawal in Jails.
3.1.2 All refusals of care required under this contract must be lnformed Refusals, one element of
which is that the individual must have decision-making capacity'
3.1.2.1. lf an individual expresses a desire to refuse a treatment, appears well, and there is no
urgency to the treatment, treatment may be delayed until an appropriately licensed
professional determines they have decision-making capacity and obtains an lnformed
Refusal,
3.1.2.2. lf an individual expresses a desire to refuse a treatment (i.e., someone who then
needs to undergo an lnformed Refusal) and either appears unwell orthe treatment is
urgent, Contractor will arrange for immediate evaluation of the individual's decision-
making capacity (i.e,, on-site or at a community hospital), and, if they have such
capacity, immediately execute an lnformed Refusal.
HCA Contract No. K5885-05 Page3of13
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04
a. lf sent to a community hospital, Contractor shall not accept the individual back at
the jail until it is clinically safe to do so, and they have regained decision-making
capacity.
3.1.2.3. Decision-making capacity shall only be determined by a medical or mental health
prescriber (e.g., physician, nurse practitioner, physician assistant) or a licensed mental
health professional at the master's level or higher. lnformed Refusal shall only be
executed by a prescriber.
3.2. Intake
3.2.1.
1 Methadone, buprenorphine, naltrexone
2 Naltrexone, acamprosate
Screen all newly admitted individuals for risk of acute withdrawal from opioids and alcohol upon
intake.
3.2.2. MOUD1, MAUD2, and other medications which support the relief of withdrawal symptoms, such
as alpha-2 adrenergic agonists (e.g., lofexidine), anti-emetics, anti-diarrheals, analgesics, and
fluid and electrolyte replacement (e.9., Gatorade@) must be offered to individuals at no charge
to the individual.
3.2.3. Offer initiation of MOUD treatment to individuals who are physically dependent on opioids, may
have withdrawal symptoms, or have disclosed recent use and anticipate withdrawal. Facilities
shall not require tapering from the illicit opioid unless clinically indicated.
3.2.4. Offer treatment for withdrawal with benzodiazepines to individuals entering the facility who are
physically dependent on alcohol, if clinically appropriate.
3.2.5. Continue MOUD and MAUD for individuals who are already taking these medications upon
entering the facility. Continue the individual on the same medication at the same dose unless
ordered otherwise by the prescriber based on clinical need, unless one of the following
exceptions is applicable:
3.2.5.1. lnjectable long-acting naltrexone may be converted to an equivalent oral dose untiljust
prior to release at which time the injectable form shall be restarted.
3.2.5.2. lnjectable long-acting buprenorphine may be converted to an equivalent oral dose until
just prior to release at which time the injectable form shall be restarted.
3.2.5.3. Oral buprenorphine may be converted to any of the three formulations available: film,
tablet with naloxone, or tablet without naloxone.
3.2.5.4. lf the individual is not pregnant, methadone may be transitioned to buprenorphine if
one of the following is applicable:
a. Contractor is not a licensed Opioid Treatment Program (OTP) and the nearest OTP
willing to collaborate with the jail to provide methadone is not within reasonable
driving distance from the jail, and the jail does not have nursing staff on site seven
HCA Contract No. K5885-05 Page 4 of 13
. Docusign Envelope lD: 700826AD-3CE3-81 5C-8194-013EF364M04
(7) days a week. The individual must be started back on methadone prior to
release if they plan to resume methadone in the community.
b. There is no OTP within reasonable distance of the individual's release residence.
3.2.5.5. Though MOUD/MAUD must not be discontinued on a policy or administrative basis
because of the presence of other illicit or controlled substances, administration of the
community-based MOUD or MAUD may be adjusted if clinically necessary due to
pharmacologic risks of drug-drug interaction.
3.2.6. Contractor shall screen for OUD and AUD without physical dependence (i.e., without a risk of
acute withdrawal) and history of opioid overdose, soon after intake'
3.2.7. Educate individuals on treatment choices and the process for continuation of access to
MOUD/MAUD during incarceration and upon release.
3.2.8. Make available and offer treatment using some formulation of methadone, buprenorphine, or
naltrexone based on a mutually agreed-upon plan between the prescriber and the individual.
The plan must take into consideration, among other clinically relevant factors, the availability of
specific medications at their residence of release.
3.2.8.1. Contractor may provide naltrexone or buprenorphine in oralformulation, with or without
naloxone while the individual is incarcerated but must offer an oralformulation of
buprenorphine WITH naloxone unless there is a clinical reason not to do so, e.9., the
individual is allergic to naloxone at release.
3.2.9. Contractor shall not allow an individualto undergo opioid withdrawal, including withdrawal using
a tapering dose of buprenorphine or methadone, unless the individual provides an lnformed
Refusal of continuing maintenance MOUD treatment after withdrawing or the individual elects
MOUD treatment with naltrexone.
3.2.9.1. ln either case, Contractor will offer the individual tapering doses of buprenorphine or
methadone supplemented, as necessary, with alpha-2 adrenergic agonists (e.9.,
lofexidine), anti-emetics, anti-diarrheals, analgesics, fluid and electrolyte replacement
(e.9., Gatorade@).
3.2.9.2. lnitiation of buprenorphine or methadone, whether for maintenance or for withdrawal,
must not be delayed for administrative reasons, e,9., unavailability of a prescriber,
beyond when they are clinically indicated to be started.
3.3. During lncarceration
3.3.1. Offer initiation of maintenance MOUD/MAUD to individuals who did not start MOUD/MAUD for
acute opioid or alcohol withdrawal as identified at intake, e.9., individuals with OUD but without
physical dependence, or individuals with AUD who underwent withdrawal.
3.3.'1.1. For all individuals initiation should begin soon enough to attempt stabilization of dosing
prior to release.
3.3.1.2. For individuals with a history of opioid overdose, initiation should begin as soon as
possible after identified.
HCA Contract No. K5885-05 Page 5 of 13
, Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04
3.3.2. Educate individuals on treatment choices and the process for continuation of access to
MOUD/MAUD during incarceration and upon release.
3.3.3. Contractor shall not use alternate-day or "balloon" dosing of buprenorphine (i.e., administering a
dose of medication on one (1) day which is intended to last for two (2) or more days).
3.3.4. Administer methadone and buprenorphine more often than one dose daily if clinically
necessary, e.g., in some pregnant or post-partum individuals, those who metabolize the
medication faster, and individuals who have side effects from large single doses.
3.3.5. Offer counseling to individuals for their OUD/AUD if they are expected to remain in jail for longer
than one (1) month. Provide MOUD/MAUD regardless of the individual's willingness to
participate in counseling.
3.3.6. There may be reasons an individualwill not continue MOUD/MAUD in the community, such as
no available treatment provider in the community to which the individual is released. lf the
individual will not continue MOUD/MAUD in the community, the decision when or if to
discontinue MOUD/MAUD prior to release must be based on a mutually agreed-upon decision
between the individual and the prescriber and must consider factors, including but not limited to,
the risks of opioid misuse or overdose during incarceration, and the individual's willingness to
receive a four-week (4-week) dose of an extended-release injectable buprenorphine just prior to
release which will provide a safe, tapered withdrawal.
3.4. Release
Contractor must accomplish the following prior to each individual's release from jail
Complete release planning and reentry coordination as soon as possible after admission to
ensure an effective plan is in place prior to release, including in the event of an unexpected
release of an individual who needs continued treatment and services.
3.4.1
3.4.2. Provide at least two (2) doses of an opioid reversal agent (e.9., naloxone or Narcan@) and
training on how to administer the medication to all individuals with OUD.
3.4.3. Schedule the first community appointment with a treatment facility for continuation of MOUD or
MAUD.
3.4.4. Provide in hand, upon release, and at no cost to the individual, a sufficient number of doses of
MOUD and/or MAUD to bridge the individual untilthe scheduled MOUD/MAUD follow-up
appointment at the selected community treatment facility.
3.4.4.1. lf an individual is on a long-acting injectable medication, the Contractor will ensure the
timing of the injectable medication ensures sustained treatment effect to bridge the
individual to the scheduled MOUD/MAUD follow-up appointment at the selected
community treatment facilitY.
3.4.4.2. lf an individual is at risk of being released directly from court, inform them prior to
going to court that they may request to be transported back to jail by staff to receive
these medications prior to going home.
HCA Contract No. K5885-05 Page 6 of 13
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364M04
3.4.4.3. ln situations where a follow-up appointment upon release cannot be made, e.9., after-
hours bail-out, give the individual enough medication to last untilthe next available
appointment at the community treatment. lf the appointment date is unknown or cannot
be reliably estimated, give the individual a 30-day supply at minimum.
3.4.4.4. ln situations where medications cannot be provided upon release, e.9., unscheduled
release at a time when medical staff are not present in jail, Contractor must ensure the
following:
a The individual is informed that they may either return to the jail in the morning to
receive bridge medications; or
b. lf no medical staff are present the following day, call in a prescription for the same
bridge medication to a local pharmacy, at no cost to the individual.
3.4.5. Assist Medicaid-eligible individuals to sign up for Medicaid or assist individuals whose Medicaid
coverage has been terminated to reestablish coverage.
3.4.6. For any individualwith Medicaid coverage, work cooperatively with the individual's Managed
Care Organizations (MCO) to facilitate re-entry benefits and continued treatment with a
community partner, including but not limited to allowing the MCO's agent timely access to the
jail and the individual.
3.5. Contract Management
3.5.1. Ensure operation specific tools, such as job descriptions, policies and procedures, and
statements of work, are developed, and staff are adequately trained, to ensure consistent and
appropriate practice.
3.5.2. Attend monthly meetings with the HCA Contract Manager to discuss Contract requirements,
compliance, and problem-solving. Attend additional meetings as required or deemed necessary
by the HCA Contract Manager.
3.5.3. Contractor shall cooperate with periodic site visits by the HCA Contract Manager or designee
and make all relevant records and personnel available.
4. REPORTING
Contractor shall complete performance monitoring activities, including the submission of timely and accurate
data reports to the HCA Contract Manager, utilizing the HCA provided templates. Further evaluation,
including on- and off-site data collection, may be conducted by HCA or an HCA-designated third party.
Reporting shall include, but is not limited to, the following:
4.1. Monthly Progress Reports
4.1 .1 . Due no later than the 1Oth day of the month following the month in which the services being
reported were provided.
4.1.2. See Schedule A-5, EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report.
HCA Contract No. K5885-05 Page 7 of 13
Docusign Envelope lD: 700826AD-3CE3-81 5C-81 94-01 3EF3644,404
4.2. Monthly Data Collection Spreadsheet
4.2.1. Due no later than the 1Oth day of the month following the month in which the services being
reported were provided.
4.2.2. See Attachment 2, MOUD Monthly Data Collection Spreadsheet'
4.3. Data Collection Format
4.3.1. HCA anticipates shifting the data collection format from MFT to Program Data Acquisition
Management and Storage (PDAMS) system during the term of this Contract. Contractor shall
continue to collect data via Managed File Transfer (MFT) method until notified otherwise by the
HCA Contract Manager in writing.
4.3.1.1. HCA Contract Manager shall notify Contractor of this change no less than ten (10)
Business Days before implementing the new collection format'
5. COST REIMBURSEMENT
The payment format for this Contract is established as cost reimbursement. Reports and receipts must be
submitted monthly with each A-19 invoice, as identified in this section and in Contract Section 3.4, Invoice
and Payment.
5.1. Allowable Expenses
Only purchases and staff time which are not part of a Medicaid billable service are allowable. Refer to
the following documents for Medicaid billing guidance and fee schedules:
5.1.1. Reentrv from a carceral settinq I Washinqton State Health Care Authoritv
5.1.2. Reentrv lnitiative Policv and Operations Guide
5.1.3. Provider billinq quides and fee schedules I Washinqton State Health Care Authoritv
5.1.4. Email questions to hcareentrvdemonstrationproiect@hca.wa.qov
5.2. Monthly Estimated Costs
5.2.1. The estimated monthly cost reimbursement is as follows:
5.2.1.1. July 1,2026 -June 30,2027
Monthly Estimated Cost Number of Months TotalCosts
$17,416 12 $209,000
5.2.2. Adjustments revising twenty-five percent (25%) or more of the Monthly Estimated Costs as
identified in this section 5.2 must be submitted to the HCA Contract Manager or designee for
approval in writing, via email, at leastfifteen (15) Business Days priorto expending the adjusted
funds.
5.2.3. HCA approval must be granted, in writing, prior to expending funds.
HCA Contract No. K5885-05 Page8ofl3
. Docusiqn Envelope lD: 700826AD-3CE3-81 5C-81 94-01 3EF364AA04
5.3. Invoicing
lnvoices must be submitted in conjunction with the monthly reports identified in this Statement of Work,
Section 4, Reporting, and as follows:
5.3.1. lnvoices shall be due no later than the tenth (101h) day of the month following the month in which
the expenses being invoiced were expended; and
5.3.2. As outlined in Contract Section 3.4, lnvoice and Payment.
HCA Contract No. K5885-05 Page 9 of 13
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364M04
ATTACHMENT 1.A
EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report
NOTE: Example below provided for reference only , the HCA Contract Manager will provide the fillable form for
Contractor use prior to the July 1 ,2026, implementation date.
1. INTAKE
n Screen all newly admitted individuals for risk of acute opioids hol upon intake
n MOUD3' MAUD4 and other medications which sup , such as
alpha-2 ad renergic agon ists (e.9., lofexidine),gesics, and fluid and
electrolyte replacement (e.9., Gatorade@) must o charge to the individual.
! Offer initiation of MOUD treatment to in lly dependent on opioids, may have
withdrawal symptoms,or have disclosed recent withdrawal. Facilities shall not
require tapering from the illicit opioid un
! Offer treatment for withdrawal with entering the facility who are
physically dependent on alcohol, if clinica
n Continue MOUD and MAUD for taking these medications upon entering the
facility. Continue the individual at the same dose unless ordered otherwise by
the prescriber based on clinical n lowing exceptions is applicable
a lnjectable long-acting naltrexone to an equivalent oral dose untiljust prior to
release at which ti ble form restarted
lnjectable long-acti converted to an equivalent oral dose until just prior to
release at which time all be restarted
a Oral rne may rted to any of the three formulations available: film, tablet with
naloxone,without
adone may be transitioned to buprenorphine if one of the
Contractor licensed Opioid Treatment Program (OTP) an d the nearest OTP willing to
a
a lf the
foll
o
laborate jailto provide methadone is not within reasonable driving distance from the
n d the ja not have nursing staff on site seven (7) days a week. The individual mustil,
be
3 Methadone, buprenorphi naltrexone
a Naltrexone, acamprosate
hadone prior to release if they plan to resume methadone in the
rs P within reasonable distance of the individual's release residence
TCONTRACTOR NAME:
CONTRACT FUNDING END:CONTRACT FUNDING START:MONTH REPORTING ON:.rrr-ffi#ffiJuly 1 ,2026
HCA Contract No. K5885-05 Page 10 of l3
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04
Though MOUD/MAUD must not be discontinued on a policy or administrative basis because of the presence
of othlr illicit or controlled substances, administration of the community-based MOUD or MAUD may be
adjusted if clinically necessary due to pharmacologic risks of drug-drug interaction.
tr Contractor shall screen for OUD and AUD without physical dependence (i.e., without a risk of acute
withdrawal) and history of opioid overdose, soon after intake.
n Educate individuals on treatment choices and the process for continuation of access to MOUD/MAUD
during incarceration and upon release.
I Make available and offer treatment using some formulation of methadone, buprenorphine, or naltrexone
based on a mutually agreed-upon plan between the prescriber and the individual. The.plan must take
into consideration, among other clinically relevant factors, the availability of specific medications at their
residence of release.
. Contractor may provide naltrexone or buprenorphine in oral formulation,'with or without naloxone
while the individual is incarcerated but must offer an oralformulation of buprenorphine WITH
naloxone unless there is a clinical reason not to do so, e.9., the individual is allergic to naloxone at
release.
n Contractor shall not allow an individual to undergo opioid'withdrawal, including withdrawal using a
tapering dose of buprenorphine or methadone, unless the individual provides an lnformed Refusal of
continuing maintenance MOUD treatment after withdrawing or the individual elects MOUD treatment
with naltrexone.
. ln either case, Contractor will offer the individualtapering doses of buprenorphine or methadone
supplemented, as necessary, with alpha-2 adrenergic agonists (e.9., lofexidine), anti-emetics, anti-
diarrheals, analgesics, fluid and electrolyte replacement (e 9., Gatorade@)).
. lnitiation of buprenorphine or methadone, whether for maintenance or for withdrawal, must not be
delayed for administrative reasons, e.g., unavailability of a prescriber, beyond when they are
clinically indicated to be started.
2, DURING INCARCERATION
tr Offer initiation of maintenance MOUD/MAUD to individuals who did not start MOUD/MAUD for acute
opioid or alcohol withdrawal.as identified at intake, e.g., individuals with OUD but without physical
dependence, or'individuals with AUD who underwent withdrawal.
. For all individuals initiation should begin soon enough to attempt stabilization of dosing prior to
release.
. For.individuals with a history of opioid overdose, initiation should begin as soon as possible after
identified.
tr Educate individuals on treatment choices and the process for continuation of access to MOUD/MAUD
during incarceration and.upon release.
tr Contractor shall not use alternate-day or "balloon" dosing of buprenorphine (i.e., administering a dose
of medlcation on one (1) day which is intended to last for two (2) or more days).
tr Administer methadone and buprenorphine more often than one dose daily if clinically necessary, e'9.,
in some pregnant or post-partum individuals, those who metabolize the medication faster, and
individuals who have side effects from large single doses.
HCA Contract No. K5885-05 Page 11 of 13
, Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364AA04
n Offer counseling to individuals for their OUD/AUD if they are expected to remain in jail for longer than
one (1) month. Provide MOUD/MAUD regardless of the individual's willingness to participate in
counseling.
n There may be reasons an individualwill not continue MOUD/MAUD in the community, such as no
available treatment provider in the community to which the individual is released. lf,the individual will
not continue MOUD/MAUD in the community, the decision when or if to discontinue MOUD/MAUD prior
to release must be based on a mutually agreed-upon decision between the individual and the
prescriber and must consider factors, including but not limited to, the risks of opioid misuse or overdose
during incarceration, and the individual's willingness to receive a four-week (4-week) dose of an
exten-ded-release injectable buprenorphine just prior to release which will provide a safe, tapered
withdrawal.
3. RELEASE
Contractor must accomplish the following prior to each individual's release from jail:
n Complete release planning and reentry coordination as soon as possible after admission to ensure an
effective plan is in place prior to release, including in the event of an unexpected release of an
individualwho needs continued treatment and services.
tr Provide at leasttwo (2) doses of an opioid reversalagent.(e.g:, naloxone or Narcan@) and training on
how to administer the medication to all individuals with OUD.
tr Schedule the first community appointment with a treatment facility for continuation of MOUD or MAUD.
n Provide in hand, upon release, and at no cost to the individual, a sufficient number of doses of MOUD
and/or MAUD to bridge the individual untilthe scheduled MOUD/MAUD follow-up appointment at the
selected community treatment facility.
. lf an individual is on a long-acting injectable medication, the Contractor will ensure the timing of the
injectable medication ensures sustained treatment effect to bridge the individual to the scheduled
MOUD/MAUD follow-up appointment at the selected community treatment facility.
. lf an individual is at risk of being released directly from court, inform them prior to going to court that
they may request to be transported back to jail by staff to receive these medications prior to going
home.
. ln situations where a follow-up appointment upon release cannot be made, e.g., after-hours bail-
out, give the individual enough medication to last until the next available appointment at the
community treatment. lf the appointment date is unknown or cannot be reliably estimated, give the
individual a 30-day supply at minimum.
ln situations where medications cannot be provided upon release, e.9., unscheduled release at a
time when medical.staff are not present in jail, Contractor must ensure the following:
o The individual id,informed that they may either return to the jail in the morning to receive bridge
medications; or
o lf no medical staff are present the following day, call in a prescription for the same bridge
medication to a local pharmacy, at no cost to the individual.
Assist Medicaid-eligible individuals to sign up for Medicaid or assist individuals whose Medicaid
coverage has been terminated to reestablish coverage.
HCA Contract No. K5885-05 Page 12 of 13
4 Docusign Envelope lD: 700826AD-3CE3-81 5C-81 94-01 3EF364A404
For any individualwith Medicaid coverage, work cooperatively with the individual's Managed Care
Organizations (MCO) to facilitate re-entry benefits and continued treatment with a community partner,
inciuding but not limited to allowing the MCO's agent timely access to the jail and the individual.
4. NOTES:
I attest that the general requirements of the MOUD/MAUD i as indicated hereinhave
DATE SIGNEDPRINTED NAME AND TITLErf
HCA Contract No. K5885-05 Page 13 of 13